Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Maui527on Jul 23, 2020 12:01am
453 Views
Post# 31305783

Should This Be Concerning...

Should This Be Concerning...From: XXX XXXXXXX
Sent: July 22, 2020 8:57 PM
To: 'Robert Farrell' <bfarrell@kalytera.co>
Cc: XXX XXXXXXX
Subject: RE: Kalytera Therapeutics - Private Placement
 
Mr. Farrell,
 
I have a had a change of heart at this point in time and I will remain invested (no choice given the given halt) with the shares I currently have, which are several million at a much higher price then the current $0.025. At this point in time I can only remain hopeful to recoup a portion of my investment, if any at all. I am discouraged to say the least that on the eleventh hour I am getting a direct email from you, as that leads me to believe that the PP is not going well. I cannot believe that I fell so hard for your company, I truly believed that there was promise with GVHD and your track record in getting it done. I have no choice but to remain hopeful, but my heart tell me otherwise and that this may go down as one of my biggest loss ever. I hope that I am wrong.
 
Sincerely,
 
XXX XXXXXXX
 
From: Robert Farrell <bfarrell@kalytera.co>
Sent: July 22, 2020 3:04 PM
To: XXX XXXXXXXX
Subject: Kalytera Therapeutics - Private Placement
 
 Hello XXX
 
Could you please complete and sign your subscription agreement today?
 
Today is the final day, so we need all completed and signed agreements today.
 
Thank you and best regards,
 
Robert E. Farrell, J.D.
President and CEO
Kalytera Therapeutics, Inc.
Mobile Phone: 415-218-3900
Email: bfarrell@kalytera.co
www.kalytera.co

<< Previous
Bullboard Posts
Next >>